0	3	The	the	DT
4	10	effect	effect	NN
11	13	of	of	IN
14	24	Toremifene	Toremifene	NNP
25	27	on	on	IN
28	31	the	the	DT
32	42	expression	expression	NN
43	45	of	of	IN
46	50	some	some	DT
51	56	genes	gene	NNS
57	59	in	in	IN
60	65	human	human	JJ
66	77	mononuclear	mononuclear	JJ
78	83	cells	cell	NNS
83	84	.	.	.

86	96	Toremifene	Toremifene	NNP
97	103	exerts	exert	VBZ
104	112	multiple	multiple	JJ
113	116	and	and	CC
117	123	varied	varied	JJ
124	131	effects	effect	NNS
132	134	on	on	IN
135	138	the	the	DT
139	143	gene	gene	NN
144	154	expression	expression	NN
155	157	of	of	IN
158	163	human	human	JJ
164	174	peripheral	peripheral	JJ
175	186	mononuclear	mononuclear	JJ
187	192	cells	cell	NNS
192	193	.	.	.

194	199	After	after	IN
200	210	short-term	short-term	JJ
210	211	,	,	,
212	214	in	in	FW
215	220	vitro	vitro	FW
221	229	exposure	exposure	NN
230	232	to	to	TO
233	246	therapeutical	therapeutical	JJ
247	253	levels	level	NNS
253	254	,	,	,
255	263	distinct	distinct	JJ
264	271	changes	change	NNS
272	274	in	in	IN
275	289	P-glycoprotein	P-glycoprotein	NNP
289	290	,	,	,
291	298	steroid	steroid	NN
299	308	receptors	receptor	NNS
308	309	,	,	,
310	313	p53	p53	NN
314	317	and	and	CC
318	323	Bcl-2	bcl-2	NN
324	334	expression	expression	NN
335	339	take	take	VBP
340	345	place	place	NN
345	346	.	.	.

347	349	In	in	IN
350	354	view	view	NN
355	357	of	of	IN
358	361	the	the	DT
362	372	increasing	increase	VBG
373	376	use	use	NN
377	379	of	of	IN
380	393	antiestrogens	antiestrogen	NNS
394	396	in	in	IN
397	403	cancer	cancer	NN
404	411	therapy	therapy	NN
412	415	and	and	CC
416	426	prevention	prevention	NN
426	427	,	,	,
428	433	there	there	EX
434	436	is	be	VBZ
437	444	obvious	obvious	JJ
445	450	merit	merit	NN
451	453	in	in	IN
454	463	long-term	long-term	JJ
464	466	in	in	FW
467	471	vivo	vivo	FW
472	479	studies	study	NNS
480	482	to	to	TO
483	485	be	be	VB
486	495	conducted	conduct	VBN
495	496	.	.	.